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Abstract
We investigated the relative immunogenicity and protective efﬁcacy of recombi-
nant X85MF1 and X85V strains of DcyaDcrpDasd-attenuated Salmonella Typhi-
murium expressing, respectively, secreted Yersinia pestis F1 and V antigens,
following intranasal (i.n.) or i.n. combined with oral immunization for a mouse
model. A single i.n. dose of 10
8CFU of X85MF1 or X85V induced appreciable
serum F1- or V-speciﬁc IgG titres, although oral immunization did not. Mice i.n.
immunized three times (i.n. 3) with Salmonella achieved the most substantial
F1/V-speciﬁc IgG titres, as compared with corresponding titres for an oral-primed,
i.n.-boosted (twice; oral-i.n. 2) immunization regimen. The level of V-speciﬁc
IgG was signiﬁcantly greater than that of F1-speciﬁc IgG (Po0.001). Analysis of
the IgG antibodies subclasses revealed comparable levels of V-speciﬁc Th-2-type
IgG1 and Th-1-type IgG2a, and a predominance of F1-speciﬁc Th-1-type IgG2a
antibodies. In mice immunized intranasally, X85V stimulated a greater IL-10-
secreting-cell response in the lungs than did X85MF1, but impaired the induction
of gamma-interferon-secreting cells. A program of i.n. 3 and/or oral-i.n. 2
immunization with X85V provided levels of protection against a subsequent lethal
challenge withY.pestis, of, respectively,60% and20%, whereas 80%protectionwas
provided following the same immunization but with X85MF1.
Introduction
Plague is a zoonotic disease caused by the Gram-negative
bacterium Yersinia pestis (Perry & Fetherstone, 1997). Two
distinct forms of plague exist, namely bubonic and pneu-
monic plague (Perry & Fetherstone, 1997). Bubonic plague,
a disease characterized by massively swollen lymph nodes, is
transmitted primarily by the bite of an infected ﬂea and the
congestion of bacteria-contaminated foods. Pneumonic
plague occurs as the result of the progress of bubonic plague,
from direct contact between infected humans (animals) by
means of droplets expelled during coughing, or from
inhalation of aerosolized Y. pestis from a biological weapon.
It usually has a short incubation period of 2–3 days, and a
fairly high mortality rate if the condition remains untreated
(Perry & Fetherstone, 1997; Titball & Leary, 1998; Inglesby
et al., 2000).
Although several antibiotics such as tetracycline and
amoxicillin have previously been used for front-line pro-
phylaxis for, as well as treatment of, plague infection (Russell
et al., 1996; Galimand et al., 1997), over time the relative
effectiveness of such a treatment regimen has been chal-
lenged as a consequence of the ever-increasing emergence of
multi-drug-resistant Y. pestis isolates (Guiyoule et al., 2001).
There is thus clearly a pressing need for the development of
an appropriate plague vaccine. The currently licensed plague
vaccine is killed whole-cell vaccine; however, it has been
shown that its effectiveness is unsatisfactory for pneumonic
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and systematic side effects (Marshall et al., 1974; Meyer
et al., 1974). In recent years, international research efforts
appear to have focused on the use of recombinant technol-
ogy to design a new vaccine candidate for immunization
for such diseases, with the principal focus being directed
towards Y. pestis F1 and LcrV (V) antigens (Titball &
Williamson, 2001). The F1 (17.5-kDa) polypeptide is a
speciﬁc virulence factor of Y. pestis, and is transcribed and
secreted into the bacteria surface by means of the
Caf system, which consists of Caf1A as an anchor, Caf1M as
a chaperone, and certain Caf1 (F1) structural proteins
(Galyov et al., 1991; Karlyshev et al., 1992). The F1
antigen is a capsular-like protein that has been previously
associated with the antiphagocytosis of Y. pestis within
mouse macrophage-like J774.A.1 cells (Pettersson et al.,
1999; Du et al., 2002). The LcrV antigen is common to all
three varieties of human pathogenic Yersiniae. It is also
involved in controlling the secretion of an array of Yersinia
outer proteins (Yops) from bacteria cytoplasm (Price et al.,
1991), and would appear to be quite closely associated
with immune suppression (Nakajima & Brubaker, 1993;
Nakajima et al., 1995; Nedialkov et al., 1997; Welkos et al.,
1998). Both the F1 and Vantigens have been tested success-
fully as potential plague-vaccine antigens, either alone or
in combination with appropriate adjuvants, following
parenteral or intranasal immunization, enabling the pro-
duction of protective immunity against plague for an
experimental animal model (Leary et al., 1995; Williamson
et al., 1995; Anderson et al., 1996; Heath et al., 1998; Jones
et al., 2006).
Live attenuated Salmonella vaccine strains have been used
as carriers of heterologous antigen(s) from bacteria, viruses
and parasites (Cardenas & Clements, 1992). Following oral
administration, Salmonella has been shown to be capable of
stimulating systemic antibody and cell-mediated immunity
(Chatﬁeld et al., 1994; Hormaeche et al., 1995). Similarly,
immunization through the intranasal route with Salmonella
has been shown to be as efﬁcient as, and even superior to,
the oral route in inducing mucosal and systemic immune
responses (Hopkins et al., 1995; Pasetti et al., 2000; Capozzo
et al., 2004). Both these approaches have also been tested in
Salmonella-based vaccine, and successfully induced protec-
tive immunity against plague in a mouse infection model
(Morton et al., 2004). Conventionally, a Salmonella vaccine
strain contains a plasmid-based expression vector, which
encodes the heterologous antigen(s) of interest, and an
antibiotic-resistance selection marker that is used, after
addition of the corresponding antibiotic, for plasmid main-
tenance. The use of such Salmonella strains has been
discouraged because of concerns over safety regarding use
in humans, and because of concerns regarding cost-effec-
tiveness, as it is necessary to produce large quantities of
antibiotics by large-scale fermentation for production of the
bacteria as inoculate (Hagg et al., 2004; Verch & Pan, 2004).
The attenuated S. enterica serovar Typhimurium strain
x8501 harbours deletion mutations in cya and crp, defective
in the synthesis of the adenylate cyclase and cyclic AMP
receptor, and asd, which encodes the aspartate b-semialde-
hyde dehydrogenase (Asd), an essential enzyme for cell-wall
biosynthesis (Nayak et al., 1998). This Asd auxotrophic
mutant was unable to grow in complex medium without
supplementationwith diaminopimelic acid (DAP), a bacter-
ia amino acid not found in eukaryotes, but, after trans-
complementation with an Asd
1 plasmid, the mutant’s
growth was restored (G´ alan et al., 1990). Hence, only Asd
1
plasmid-carrying cells can grow in DAP-free medium, mak-
ing the Asd
  Salmonella strain dependent on the plasmid
maintenance, owing to the balanced lethal relationship
between vector and host systems (Nakayama et al., 1988;
G´ alan & Sansonetti, 1996). Recently, a multicopy, stable
Asd
1 antigen-expressing vector, pAY3493, has been specially
designed to express the secreted recombinant pneumococcal
surface protein (rPspA) antigen by means of the fusion of
the b-lactamase signal sequence in an Asd
  Salmonella
vaccine strain (Kang et al., 2002). This particular strain of S.
typhimurium x8501 (pYA3493) has been demonstrated to be
capable of inducing an enhanced immune response to rPspA.
In our study, we describe the construction of a
DcyaDcrpDasd-attenuated strain of S. typhimurium expres-
sing either the Y. pestis F1 or Vantigens as a candidate plague
vaccine. Furthermore, we undertook an assessment of the
immune response of test mice and of the protective efﬁcacy
of these Salmonella-derived vaccines against plague follow-
ing mucosal immunization with such vaccines within a
mouse infection model.
Materials and methods
Bacterial strains, plasmid and growth condition
Salmonella enterica serovar Typhimurium strain x8501 is
aDcrp-28DasdA16 mutant, and pYA3493 is an Asd
1 and
pBRori vector containing b-lactamase signal sequence
(Kang et al., 2002). The Asd
  mutant x8501 strain was
cultivated at 371C in Luria–Bertani (LB) broth or Luria agar
(L-agar) containing diaminopimelic acid (DAP, 50mgmL
 1;
Sigma Chemical Co., St Louis, MO). The recombinant
Escherichia coli DH5/pUC18-CafAMF1 (EC1853F strain)
harbouring the Caf operon used to produce the F1 antigen
was constructed as describedpreviously (Titballet al.,1997).
Construction of recombinant plasmid
expressing secreted F1 or V antigen
Standard DNA-manipulation techniques, such as PCR,
agarose gel electrophoresis, restriction-enzyme digestion,
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according to the procedures described previously (Sam-
brook et al., 1989). Plasmid pYA3495 was obtained by
replacing the multiple cloning site of pYA3493 with M
oligonucleotides (50-GAATTCGAGCTCGGTACCCGGGG
ATCCAAGCTT-30) containing EcoRI/SacI/KpnI/BamHI/
HindIII sites. Isolation of the pMT1 and pYV1 plasmids,
endogenous plasmids from Y. pestis EV76S, was performed
according to the method described in Kado & Liu (1981).
Construction of the F1-expressing plasmid was by means of
a two-step process. First, a speciﬁc DNA fragment encoding
Caf1 was ampliﬁed by PCR from pPMTwith primers PF1B
(50-GTTCCGGGATCCATGAAAAAAATCAGTTCCGTT-30,
underlined for the BamH1 linker region) and PF1H (50-
GTTCCGAAGCTTTTATTGGTTAGATACGGTTAC-30, un-
derlined for the HindIII linker region), cleaved by BamH1/
HindIII, and cloned into pYA3495 to yield pYA3495F1.
Second, a PCR-derived product containing Caf1M and its
promoter region ampliﬁed from pMT1 with primers
PM11E (50-GTTGAATTCTATCAAAATTAGCTATTTGCG-
CAA-30, underlined for the EcoR1 linker region) and
PM12BG (50-GTTAGATCTAAATATTACCTCTATCGAA-
TAATC-30, underlined for the BglII linker region) was
cleaved with EcoRI/BglII, and this product was cloned into
pYA3495F1with EcoRI/BamHIcleavage in order toyield the
expression plasmid pYA3495MF1. Similarly, the V-encoding
gene was ampliﬁed from pYV with the primers PV11H
(50-GTTCCGAAGCTTTCATTTACCAGACGTGTCATC-30)
and PV12B (50-GTTCCGGGATCCATGATTAGAGCCTAC
GAACAA-30), cleaved by EcoRI/BglII, and cloned into the
EcoRI/BamHI site of pYA3495 in order to yield pYA3495V.
The resulting plasmids from pYA3495MF1 and pYA3495V
were transformed into the S. typhimurium strain x8501 by
electroporation (Bio-Rad, Hercules, CA) in order to raise
the Salmonella X85MF1 and X85V strains, respectively.
In vitro and in vivo expression of
F1 and V antigens
For in vitro expression of the F1 and V antigens, bacterial
strains X85MF1 and X85V were cultured in LB broth at
371C incorporating 200-r.p.m. shaking for a period of 24h.
Subsequent to harvesting the cultures by centrifugation
(7000g, 10min), the soluble fraction was concentrated
using a low-molecular-weight cut-off ﬁlter (10kDa, Amicon
Ultra, Millipore Co. Bedford, MA), and the cell-pellet
fractionwas subjected to protein extraction using BugBuster
Protein Extraction reagent (Novagen Inc., Madison, WI)
following the procedures recommended by the manufac-
turer. Expression of F1 and V was conﬁrmed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) separation of each sample and analysed by immuno-
blotting using anti-F1/V-speciﬁc monoclonal antibodies
(F1-4B5-3 and V-4H-10, laboratory collection). The rele-
vant reactive polypeptides were detected by means of the
chemiluminescent substrate super signal (Pierce, Rockford,
IL). Expression of F1 and V was also examined within a
mouse macrophage-like cell line J774.A1 (ATCC TIB 67)
following a series of protocols as described previously
(Morton et al., 2004). Brieﬂy, the J774.A1 cell line was
cultured in a six-well slide-chamber containing Dulbecco
minimal essential medium (DMEM; GIBCO BRL, Grand
Island, NY) supplemented with 10% fetal calf serum (FCS;
GIBCO BRL). Mouse macrophage cells were then infected
with Salmonella X85MF1, X85V or the control x8501/
pYA3493 strain, as appropriate, at a multiplicity of infection
of 50:1, and subsequently incubated at 371C in a humidi-
ﬁed atmosphere containing 5% CO2-in-air for a period of
1h. Following this, the extracellular bacteria present were
killed by the use of gentamicin (100mgmL
 1), and the cells
were then incubated for a further period of 24h. Subsequent
to incubation, macrophage cells were washed in PBS, ﬁxed
with 4% formaldehyde, and incubated with the mouse anti-
F1 or -Vantigen antibody for a period of 1h. Following PBS
washing, the macrophage cells were incubated with a cock-
tail solution containing Alex-Red conjugated goat anti-
mouse IgG and phallodin ﬂuorescein isothiocyanate
(FITC)-conjugated rabbit anti-mouse antibody (Molecular
Probes Inc., Eugene, OR) in order to detect the speciﬁc F1/V
antigen-antibody and to probe the tublin in order to
examine the morphology of J774A.1 cells. Finally, coverslips
were mounted onto the slides and slides were visualized
using a ﬂuorescence confocal microscope (Leica DM IRE2;
Zmst-Leitz-Strasse, Wetzlar. Germany).
Immunization of mice with Salmonella
Groups of ﬁve, 8-week-old female BALB/c mice were
purchased from the Animal Center of Taiwan University.
Test mice were inoculated with recombinant S. enterica
serovar Typhimurium vaccine X85MF1, X85V or x8501/
pYA3495 (1–3 10
8CFU in a 20-mL PBS aliquot) via an
intranasal pathway in the right naires using a 20mL Gilson
pipette, the mice being allowed to inhale the bacteria as
previously described (Pasetti et al., 2000). Alternatively,
mice were orally inoculated with an equivalent dose of
Salmonella suspended in 0.5mL of PBS. The immunization
regimens consisted of either i.n. or oral-priming with two
subsequent i.n. boostings (at 2-week intervals for each
boost) with Salmonella vaccine.
Measurement of serum antibody
Mice werebled via the tail vein on day14 subsequent to each
immunization. Serum samples were assayed for IgG anti-
body titres speciﬁc for F1 and V by means of an enzyme-
linked immunosorbent assay (ELISA) (Sambrook et al.,
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strain was puriﬁed to homogeneity by size-exclusion chro-
matography as described previously (Andrews et al., 1996).
The puriﬁed His6-Vantigenwas preparedfrom recombinant
E. coli DH5/pQE30-lcrV expressing Y. pestis V using an
Ni-NTA superﬂow column by FPLC (fast-performance
liquid chromatography; Amersham Pharmacia Biotech,
Uppsala, Sweden). Polystyrene 96-well microtitre plates
were coated with puriﬁed F1 or V (100ngwell
 1). Serum
samples obtained from mice in the same experimental group
werepooled and diluted serially. A 100-mL volume of diluted
samples was added to each well of the microtitre plate in
duplicate and incubated for 2h at 371C. Following this, the
horseradish peroxidase (HRP)-conjugated goat-anti mouse
IgG (H1L) or IgG subclass (Southern Biotechnology, BD)
was added, it functioning as detector antibody for a speciﬁc
serum antibody, and the substrates o-Phenyldiamine dihy-
drochloride (OPD) and H2O2 were added. Solution absor-
bance was measured at 490nm (A490nm) using an ELISA
reader, and antibody concentrations were calculated by
interpolating regression-corrected OD490nm values for the
diluted sample according to the dilution produced by a
known concentration (9.8 312ngmL
 1) of puriﬁed IgG,
IgG1 or IgG2a antibodies that had bound to a microplate
that had been pre-coated with goat anti-mouse Ig.
Evaluation of antibody- and cytokine-secreting
cell numbers in the spleen and lung
The modiﬁed enzyme-linked immunospot (ELISPOT; Eyles
et al., 2004) assay was performed to enumerate the anti-
body-secreting cells (ASC) against F1 and V in the spleen
and lung of immunized and naı ¨ve mice in order to deter-
mine the potential cellular immune response to immuniza-
tion. Brieﬂy, Immobilon-P ﬁxed (Multi Screen-IP,
Millipore) 96-well microtitre plates were coated with
100mgmL
 1 of recombinant F1 or Vantigen (10mgmL
 1 in
PBS), incubated overnight at 41C, and then blocked with
200mL of complete culture medium (RPMI 1640 containing
10% FBS and 1% penicillin–streptomycin) for a period of
1h at room temperature. Following this, 100mL of spleen-
cell suspension (derived from individual mice), at various
densities ranging from 1 10
5 to 2 10
6mL
 1 in complete
culture medium, was added to antigen-ﬁxed 96-well micro-
titre plates in triplicate, and the plates were placed in a
humidiﬁed (5% CO2-in-air) incubator at 371C for 24h. The
plates were washed, and then incubated with aviden-HRP-
conjugated MAb against mouse Ig (IgG, A; KPL, Gaithers-
burg, MD) at 371C for a period of 1h, followed by washing
three times with PBS containing 0.1% Tween-20. Finally,
100mL of 3-amino-9-ethylcarbazole substrate (Sigma) was
added to each well, and the plates were incubated at room
temperature for various periods ranging from 15 to 60min,
following which reactions were stopped by washing wells
once with distilled water. Reddish-brown coloured ‘spots’
were enumerated and scored for Ab-forming cells under a
dissecting microscope. In order to assess the number of
cytokine-secreting cells, equal volumes of the F1 or V
protein (40mgmL
 1) were added to the cells in test wells of
plates, and incubated for 24–48h under normal conditions
for in vitro stimulation. Subsequent to washing, the cells
were coincubated with 2mgmL
 1 biotinylated anti-IL-10
and/or IFN-g antibody (Pharmingen) and examined micro-
scopically, as described previously (Eyles et al., 2004). The
data were expressed as the mean number of cytokine- or
antibody-secreting cells SE/10
5 6 cells.
Yersinia pestis challenge
Yersinia pestis (Yokohama-R strain) cultured in brain/heart
infusion agar (Difco, Sparks, MD) plates for 48h was
collected and prepared for subsequent inoculation using
PBS. Bacterial counts were enumerated by plating the dilute
of inoculate on a Congo-Red plate as previously described
(Andrews et al., 1996). Groups of eight BALB/c mice were
individually intraperitoneally (i.p.) injected with the viru-
lent Y. pestis, with doses ranging from 2 10
4 to 2CFU at
10-fold dilutions. The median lethal dose (LD50) end-point
was determined to be at about 15CFU according to the
Reed–Muench method (Welkos & O’Brien, 1994). Two
weeks subsequent to ﬁnal immunization, i.e. on day 43 after
primary immunization, mice were challenged i.p. with
1–2 10
3CFU (100 LD50)o fY. pestis in a 0.5mL PBS
aliquot. The challenge studies were conducted in a biosafety
level-3 containment facility, following the standard operat-
ing procedures for the facility.
Statistical analysis
Statistical analysis was performed using the computer
program MICROSOFT EXCEL Ver. 6.0. Levels of significance of
difference in antibody response between the tested groups
were determined by means of a two-tailed Student’s t-test.
Fisher’s exact probability test was performed to compare the
mortality for the immunized group of mice with the
corresponding controls. Avalue of P   0.05 was considered
a statistically significant difference between tested datasets.
Results
Secreted expression of F1 and V antigens
It has previously been reported that the Caf1M chaperone
protein is required for successful secretion expression of the
hIL-1b-Caf1 chimera protein on cells of recombinant E. coli
(Galyov et al., 1991). We thus elected to incorporate Caf1M-
Caf1 into the expression vector pYA3495. The structure of
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antigens is depicted in Fig. 1. The lysate derived from
various fractions of the S. typhimurium x8501/pAY95MF1
(X85MF1) and x8501/pAY95V (X85V) cultures were sepa-
rated by SDS-PAGE, and speciﬁc proteins were examined by
immunoblot assay. A fairly large polypeptide was observed
from the culture supernatant as well as from the cell-pellet
fraction, it being c. 17 and 37kDa, respectively, for X85MF1
andX85V (Fig.2). Themajorityof rF1and rV was located in
the cell-pellet fraction, and c. 2–5% of the total rF1/V was
present in the culture supernatants. This result indicates that
rF1/V is highly expressed and is actively secreted via the
secretion machinery from the construct. Following this, the
levels of rF1 and rVexpression in X85MF1 and X85V strains
were quantiﬁed using an alkaline phosphatase-conjugated
ELISA procedure. Samples of X85MF1 strain were shown to
express c.5 0 mg rF1 per 10
9CFU cells. In contrast, the
expression level for the X85V strain reached as substantial a
level as 250–300mg rV per 10
9CFU cells. Immunoblotting of
knownquantitiesofpuriﬁedproteinsalsoconﬁrmedagreater
yield of V than of F1 antigen for X85Vand X85MF1 samples.
Expression of F1 and V within macrophage-like
J774.1A cells
In order to investigate F1/V expression in vivo, Salmonella
bacteria were inoculated into cultured J774.1A cells, and the
presence of rF1/V within macrophage cells was subsequently
examined by confocal microscopy of immunoﬂuorescently
labelled X85MF1 and X85V. The results revealed that F1/V
antigens were actively expressed inside the J774.1A cells, as
indicated by the presence of positively ﬂuorescent images of
X85MF1- and/or X85V-infected cells, but this was not the
case for the cells infected with Salmonella containing vector
alone (X8501; Fig. 3).
IgG antibody responses to F1 and V antigens
Groups of BALB/c mice that had undergone a series of two
oral administrations of 10
8CFU of S. typhimurium x85MF1
and/or x85V on day 0 and day 14 did not reveal any
induction of signiﬁcant serum levels of IgG antibody for
either F1 or Vantigen (data not shown). Thus, the test mice
were primed by the oral or i.n. route and boosted by i.n.
immunization on days 14 and 28 of the experiment in order
to attempt to assess the immunological response to the
Salmonella vaccine, the sera of these immunized mice being
collected on days 14, 28 and 42 after primary immunization.
The level of serum anti-F1/V IgG titres elicited in immu-
nized mice was found to be differently dependent upon the
speciﬁc immunization regimen undertaken (Fig. 4a and b).
In both the i.n. 3 and oral-i.n. 2 immunization regi-
mens, Salmonella induced the anti-F1/V titres to a signiﬁ-
cantly greater level than was the case for the control mice.
Furthermore, the i.n. prime–boost immunization regimen
with either X85MF1- or X85V-produced vaccine induced a
signiﬁcantly greater level of anti-F1/V titres compared with
asd ss CafMF1 or LcrV 5ST1T2
BgllI BamHI BglII/BamH1 XbaI Nco BspHI
pBR ori Ptrc
HindIII
Fig. 1. Plasmids used for the expression of Yersinia pestis F1 or V antigen for an attenuated Salmonella typhimurium strain. The Y. pestis CafMF1-
or LcrV-encoding gene was cloned into the expression vector pYA3495 (see ‘Materials and methods’ section) downstream of the Bla-secretion
system. This Bla-secretion system consisted of the b-lactamase signal sequence and 12 amino-acid residues of the N-terminus of the mature
b-lactamase signal sequence, which derived from plasmid pBR322, and which was expressed under the control of the Ptac promoter. 5ST1T2
is a transcriptional terminator.
M CL 20 100 500
M CL 20 100 500
x85MF1 rF1 (ng)
x85V rV1 (ng)
F1
V
KDa
KDa
20
15
30
40
(a)
(b)
Fig. 2. Comparison of Yersinia pestis F1 and V antigen expression
in vitro in a Salmonella strain. The overnight cultures of (a) X85MF1 and
(b) X85V bacterial strains were fractionated, separated by SDS-PAGE,
and then probed,separately, with mAb against F1(4B5-3) and V (4H-10).
Samples equivalent to 5 10
7CFU of X85MF1 and 10
7CFU of X85V
from overnight culture of bacteria lysate were loaded into SDS-PAGE.
Lanes codes: M, the supernatant fraction collected from centrifugation
following overnight culture; CL, total cell lysate. Various amounts of
puriﬁed rF1 and V protein (in ng) are shown at the top of the ﬁgure, and
molecular-weight markers (in kDa) are indicated on the right-hand side
of the ﬁgure.
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regimen (Po0.001). The level of test-mouse serum anti-F1/
V titre was elevated following the i.n. boost, with a noted
two- to sixfold increase in levels of antibody titre for each
booster, irrespective of the route of priming. The highest
level of serum anti-F1/V titre that was achieved followed
three i.n. doses of vaccine. Interestingly, levels of serum anti-
V titres elicited by such immunization regimens were found
to be signiﬁcantly greater than was the case for correspond-
ing anti-F1 IgG titres, this being the case at all dosing levels
investigated (Po0.001), whereas such an immunization
regimen with Salmonella induced only a low, but detectable,
level of F1/V-speciﬁc serum IgA (data not shown).
IgG antibody subclass responses to
F1 and V antigens
Sera prepared on day 14 subsequent to mice having been
primed or boosted with either Salmonella vaccine were
further analysed to ascertain the serum IgG1: IgG2a subclass
ratio as an indirect assessment of the T helper-cell response
bias (Mosmann & Coffman, 1989). The results revealed that
the IgG1/IgG2a proﬁles developed in test mice appeared to
differ depending on the vaccine antigen involved. Mice
i.n. 3 or oral-2 i.n. immunized with X85MF1 tended to
experience a Th1-type response, as evidenced by a predomi-
nant F1-speciﬁc IgG2a response to immunization. By con-
trast, a mixed Th1/Th2-type response, as indicated by
similar levels of IgG1 and IgG2a being present in sera,
developed following the same immunization regimen with
X85V (Fig. 5a and b).
Mucosal and cell-mediated immune responses
induced by Salmonella x85MF1 and x85V
vaccines
As vaccination through the intranasal route features the
potential to induce mucosal protective immunity (Huang
et al., 2001), we investigated IgG and IgA antibody-secreting
cells (ASC) in the lung tissue of test mice. The frequency of
the presence of mucosal and systemic ASC following i.n. 3
immunization with X85MF1/V was also determined. The
F1/V-speciﬁc IgG ASC in the lung of test animals was shown
to be fairly low when compared with those ASC detected in
the spleen; however, F1/V-speciﬁc IgA ASC was hardly ever
seenwithin lung tissue. In order to test whether mice i.n. 3
immunized with X85MF1/V developed any cell-mediated
immune response to the vaccine antigen, the presence of F1/
V-speciﬁc IFN-g- and IL-10-secreting cells was determined
in the spleen and lung. A greater number of F1-speciﬁc than
of V-speciﬁc IFN-secreting cells was detected both in the
spleen and the lung. By contrast, the frequency of V-speciﬁc
Fig. 3. Confocal immunoﬂuorescent micro-
scopy images of Yersinia pestis F1- and V-anti-
gen expression for X85MF1 and X85V bacterial
strains within mouse macrophage-like J774 A1
cells. The J774 A.1 cells were infected with the
Salmonella vaccine strain, and the intracellular
bacteria were probed with anti-F1 or anti-V
mAb and then detected with Alex-Red conju-
gated anti-mouse IgG (red). The cell morphol-
ogy, as characterized by the cytoskeleton, was
observed by Phllodin-FITC-conjugated antitubu-
lin antibody (green).
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63 Mucosal immune responses to Salmonella producing plague F1/VantigenIL-10-secreting cells was signiﬁcantly greater than that of
F1-speciﬁc IL-10-secreting cells (Fig. 6a and b). Further-
more, stronger F1/V-speciﬁc IFN-gand IL-10 cytokine re-
sponses were elicited for the lung tissue than for spleen
tissue following the i.n. 3 immunization regimen with
Salmonella vaccine.
Protection of immunized mice against lethal
challenge with Y. pestis
Two weeks following oral-i.n. 2 or i.n. 3 immunization
with Salmonella (X85MF1 or X85V), mice were i.p. chal-
lenged with 2 10
3CFU of Y. pestis, and subsequent test-
animal survival was recorded daily for the subsequent 14-
day period. All the mice immunized with Salmonella x8501/
pYA3495 (control group) died by day 5 post-immunization.
Mice orally primed and i.n. boosted twice (oral-i.n. 2)
and/or i.n. 3 immunized with X85V experienced, respec-
tively, 20% and 60% protection against a lethal dose of
Y. pestis challenge. This contrasts with a corresponding
ﬁgure of 80% protection provided by the same immuniza-
tion regimen but using X85MF1 (Fig. 7).
Discussion
The use of the Salmonella vaccine strain as a delivery system
for the guest antigen(s) takes advantage of a variety of
prevailing factors, namely the relative ease of antigen
preparation, the possibility of vaccine self-administration,
the use of a noninvasive method of immunization for
vaccine development, and the reasonably cost-effective
nature of such an immunization modality. All of these
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64 W.-T. Liu et al.features could facilitate the wide-spread use of such a
vaccine. In the present study, we used a mouse model to
investigate the immunological responses, at both systemic
and mucosal levels, to administration of the recombinant
Salmonella typhimurium strain expressing either the Y. pestis
F1 or Vantigens by two distinct routes of mucosal immuni-
zation. These constructs of X85MF1 and X85V proved to be
fairly stable in vitro following 40–50 generations of bacterial
culture in antibiotic-free conditions, whereas following i.n.
and/or oral administration to test mice the constructs
appeared to diminish in persistence in test-animal spleens
and lungs when compared with the control strain (x8501/
pYA3495) over 5 days. For example, fewer than 5CFU of
vaccine organisms were observed to be present in the spleen
or liver at 24h postadministration of Salmonella x85MF1/V
strains, compared with 100–200CFU per liver or spleen for
the control strain, indicating that the vaccine strains seemed
to impair colonization. Although the F1 and Vantigens were
highly expressed and efﬁciently secreted by Salmonella
X85MF1 and X85V in vitro,a t3 71C in Luria agar only the
V antigen, and not the F1 antigen, was detected on the cell
surface of the bacteria, as deduced by immunoﬂuorescent
microscopy imagery of X85MF1/V probed with speciﬁc
mAb (data not shown). Such a combination of results is
probably associated with the absence of the Caf1A anchor
protein in the Caf1M-Caf1-secretion system of the expres-
sing vector, owing, presumably, to the essential roleof Caf1A
for surface localization of Caf1 (Zavialov et al., 2001). To the
best of our knowledge, however, at the time of writing it
is unknown whether F1 secretion is independently
controlled by the Caf1M-Caf1-secretion system or by the
interaction of F1 with the lactamase signal sequence. Ex-
pression of F1 and V antigens was also clearly detected
within vaccine-infected mouse macrophage-like J774A.1
cells (Fig. 3). No ctytotoxic effect upon cultured cells was
elicited by infection with X85MF1 and/or X85V strains.
Animals that were administered Salmonella x85MF1/V by
an i.n. or an oral route did not reveal any sign of sickness
during the study. The serum antibody response of test
animals was signiﬁcantly induced by a single i.n. dose of
Salmonella, although the corresponding oral immunization
did not elicit such a result. The reason(s) for this outcome is
unclear at present; it may be because the oral Salmonella
vaccine fails to express the plague antigen stably (Dunstan
et al., 2003). The most pronounced level of serum IgG noted
herein was achieved for test animals following three i.n.
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65 Mucosal immune responses to Salmonella producing plague F1/Vantigendoses of Salmonella: the level appeared to be statistically
signiﬁcantly greater than the corresponding value for
the oral-primed and i.n.-boosted (twice) immunization
regimen using the same vaccine. Immunization with Salmo-
nella stimulated a strong V-speciﬁc IgG response (mean
antibody concentration log10 4.96–5.9ngmL
 1), a response
clearly greater than the corresponding F1-speciﬁc IgG anti-
body response (log10 4.17–4.85ngmL
 1). Such an outcome
may possibly be related to the greater level of V antigen
expression, as compared with F1 expression, that occurred
within Salmonella. Moreover, this outcome may also be
related to V antigen, but not F1 antigen, expression on the
cell surface of the Salmonella bacterium. These two features
that in concert appeared to enhance the antibody responses
of immunized test animals, whereas in contrast all the
immunized mice revealed the induction of rather low levels
of serum F1/V-speciﬁc IgA (data not shown).
The dominant species of the F1-speciﬁc IgG subclass is
IgG2a (Fig. 5a), the presence of this immunoglobulin being
indicative of Th1-type immunity. This result would appear
to be consistent with the results of a number of previous
studies using Salmonella-delivered antigen (Leary et al.,
1997; Bullifent et al., 2000; Morton et al., 2004). Similar to
the results of Garmory et al. (2003), immunization with
X85V appeared to induce different levels of V-speciﬁc
IgG1 and IgG2a, but there was not much variation in
the respective levels elicited by i.n.  3 and oral-i.n.  2
immunization (Fig. 5b). We speculated that this discrepancy
in IgG-subclass proﬁle between the F1 and the V antibody
responses may have been associated with differences in the
localization of expressed antigen for X85MF1 and X85V.
Although the challenge route, strain and dose of virulent Y.
pestis used in this study differed from those used in a
number of previous studies (Morton et al., 2004), the
relative protective efﬁcacy afforded to test mice by vaccina-
tion with X85MF1 was comparable with that reported for
intranasal immunization with S. typhi vaccine expressing F1
(Garmory et al., 2003; Morton et al., 2004). It would thus
appear that the relative efﬁcacy of X85V vaccination is
superior to the reported effect of using orally presented V-
antibody-produced Salmonella vaccine (Garmory et al.,
2003), although the former would appear to produce results
that are inferior to that of vaccination with the DNAvaccine
expressing V-tPA (human plasminogen activator signal
sequence) fusion protein (Wang et al., 2004).
A number of related studies have indicated that antibody-
mediated immunity is important for protection against
plague (Titball et al., 1997; Williamson et al., 1999).
Concurring with this observation, our results have revealed
fairly high levels of antibody responses to immunization of
test mice with Salmonella-F1/V vaccine, an outcome that
would appear to provide better protection for mice counter-
challenged with Y. pestis than would be expected to be the
case for low levels of antibody responses to F1/V, suggesting
that the F1- or V-speciﬁc IgG antibody response is positively
correlated with the protective efﬁcacy of vaccination of test
mice with X85MF1 and/or X85V (Figs 4 and 7). Surpris-
ingly, both the i.n. 3- and oral -i.n. 2-immunized mice
experienced a similar level (80%) of protection against
plague, and for these two immunization modalities only
a subtle difference in time to death was seen, despite the
elicited anti-F1 IgG antibody responses being signiﬁcantly
different. Nevertheless, when the same immunized mice
were challenged with Y. pestis on day 56 subsequent to
primary immunization, 80% (i.n. 3) and 60% (oral-
i.n. 2) of mice survived such challenging (unpublished
results). Furthermore, when we compared the antibody
response on day 56 with the corresponding anti-F1 IgG
titres determined on day 42 postimmunization we noted
that there was a concomitant two- to threefold increase in
the serum anti-F1 IgG antibody titres for the i.n.  3 group,
whereas a slight decline in the serum anti-F1 IgG titres for
animals from the oral-i.n.  2 group was seen (data not
shown). Such a result suggests that an intranasal prime–
boost immunization regimen using X85MF1/V is more
likely to elicit a persistently sustained high level of antibody
response than would appear to be the case for an orally
primed i.n.-boosted (twice) immunization regimen; how-
ever, such so-elicited immune responses do not appear to
provide full protection against i.p. challenge withY.pestis for
test mice. Hence, it would appear that some enhancement of
the immune response elicited by immunization with the
X85MF1 and X85Vvaccines isnecessary for improvement of
the antiplague efﬁcacy. Strategies such as heterologous
prime–boost immunization regimens (Londono-Arcila
et al., 2002; Glynn et al., 2005), in vivo inducible gene-
expression techniques, and the incorporation of an immu-
nity-modulating agent into the protective antigen are stra-
tegies that have been developed recently and that have been
used to improve the relative immunogenicity of Salmonella
vaccine (Atkins et al., 2006); they may pave the way for the
future use of X85MF1/V to this end. Furthermore, it would
also appear to be possible to introduce, either alone or in
combination, the F1/V antigen-expressing vector into the
S. typhi vaccine strain as a candidate antiplague vaccine
in order to test the vaccine further for subsequent human
use. A recent study demonstrated that oral delivery of
Salmonella-(F11V) antigens elicits both F1- and V-speciﬁc
antibody responses and confers enhanced antiplague efﬁ-
cacy to treated mice as compared with either F1 or V
responses alone, emphasizing the potential application of
combined (F11V) immunization (Yang et al., 2007).
The induced F1-speciﬁc IgG antibody response was
shown to be signiﬁcantly less pronounced than the V-
speciﬁc antibody response in the serum of the immunized
mice (Po0.001) (Fig. 4). Furthermore, the deemed
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66 W.-T. Liu et al.mechanism of action of X85MF1 appeared to conﬁrm the
ability of the vaccine to confer better protection aganist
plague for recipient animals than what appeared to be the
case for X85V vaccination, this probably being the result of
the functionally different virulence roles of F1 and V
antigens in plague pathogenesis (Price et al., 1991; Du
et al., 2002). In addition, the discrepancy in protective
efﬁcacy between the two agents may be attributable to the
different cell-mediated response produced by the adminis-
tration of X85MF1 and X85V, at both systemic and mucosal
levels, as evidenced by the presence of F1/V-speciﬁc IgG
IL-10- and IFN-g-secreting cells in the spleen and lung of
i.n.-immunized mice (Fig. 6). In particular, X85V vaccine
appeared to induce high levels of IL-10 postvaccination, but
its relative antiplague efﬁcacy was somewhat impaired as
regards the production of IFN-gcompared with X85MF1
(Fig. 6). V-mediated IL-10 secretion is thought to be
involved in plague pathogenicity by preventing the release,
to serum, of proinﬂammatory cytokines, such as TNF-a and
IFN-g, postinfection, and by subsequently suppressing the
innate immune responses to plague infection (Nakajima &
Brubaker, 1993; Brubaker 2003). Furthermore, certain
proinﬂammatory cytokines have been shown to provide
protective efﬁcacy against Y. pestis. For example, passive
immunization with TNF-a and IFN-g has been shown to
protect mice from plague infection (Nakajima & Brubaker,
1993), and the relative antiplague efﬁcacy of F1- and V-
based vaccine has been demonstrated to be reduced for Stat-
4-deﬁcient mice, animals which are typically deﬁcient in the
production of type-1 cytokine responses (Elvin & William-
son, 2004). The presumably high levels of IL-10 release
following vaccination do not appear to be desirable for
effective plague vaccination. Recently, a study using a V
variant lacking amino-acid residues 271–300 revealed that
such a vaccine elicited uncompromised protective efﬁcacy
while signiﬁcantly reducing the induction of IL-10, an
outcome that re-enforces the abovementioned notion
(Overheim et al., 2005). Together, these results appear to
imply that the cell-mediated, as well as the humoral,
immune responses elicited by Salmonella vaccine adminis-
tration play an important role as regards protection against
plague for vaccinated test animals.
In conclusion, the present study demonstrates that i.n.
immunization with the X85MF1 and X85V bacterial strains,
unlike oral immunization with the same strains, induces a
strong antibody response in recipient test mice. Further-
more, these vaccines, which probably elicit different proﬁles
of immune responses, independently reveal immunological
correlation with the protection against plague as afforded to
vaccine-recipient test mice. In addition, X85MF1 appears to
demonstrate a greater potency than X85V in terms of the
overall antiplague protective efﬁcacy of such prime–boost
immunization regimens. Our ﬁndings indicate that those
Salmonella strains expressing F1 and/or Vantigen are able to
induce a profound immune response for recipient animals
following i.n. vaccination, or following i.n. vaccination
combined with delivery of vaccine via other routes, and that
such types of vaccination are able to provide suitable
protection for test animals from the deadly challenges of
Y. pestis infection, thus providing a broad perspective for
enhanced plague-vaccine development.
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